NF-κB-IN-1

NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells In Vitro NF-κB-IN-1 (compound 17) (0.001-100 μM; 72 h) inhibits the growth of A549, H1944, H460 and H157 cells, with GI 50 s of 0.72, 0.07, 0.13, and 0.16 μM, respectively. NF-κB-IN-1 (0.5-25 μM; pretreated for 30 min or 4 h) potently blocks the IκB phosphorylation and degradation in A549 cells. NF-κB-IN-1 (0.1-100 μM; pretreated for 30 min) dose-dependently inhibits the TNFα-induced nuclear translocation of NF-κB in A549 cells, with an IC 50 s of 1.0 μM. NF-κB-IN-1 (0.1-0.4 μM; 9 d) inhibits lung cancer clonogenic activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: A549, H1944, H460 and H157 cells Concentration: 0.001, 0.01, 0.1, 1, 10, 100 μM Incubation Time: 72 hours Result: Decreased viability of lung adenocarcinoma cells A549 and H1944, quamous cell carcinoma cells H157, and large cell carcinoma cells H460 in a dose-dependent manner. Western Blot AnalysisCell Line: A549 cells Concentration: 0.5, 1.0, 2.5, 5.0, 10.0, 25.0 μM Incubation Time: Pretreated for 30 min or 4 h Result: Blocked IκB phosphorylation, with an IC 50 of 2.8 μM. Blocked IκB degradation in a dose-dependent manner. Form:Solid IC50& Target:IKK

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet